Satsuma Pharmaceuticals (NASDAQ:STSA) Given Consensus Rating of “Strong Buy” by Analysts
Shares of Satsuma Pharmaceuticals (NASDAQ:STSA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $35.00 for the company and are forecasting that the company will post ($0.72) earnings per share for the current quarter, according to Zacks. Zacks has also given Satsuma Pharmaceuticals an industry rank of 51 out of 254 based on the ratings given to related companies.
Several analysts recently issued reports on the company. SVB Leerink lifted their target price on Satsuma Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, March 11th. Credit Suisse Group reiterated a “buy” rating and set a $32.00 price objective on shares of Satsuma Pharmaceuticals in a research report on Wednesday, May 6th. ValuEngine upgraded shares of Satsuma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 5th. Mizuho reaffirmed a “buy” rating and issued a $32.00 price target on shares of Satsuma Pharmaceuticals in a report on Monday, June 1st. Finally, Zacks Investment Research lowered Satsuma Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd.
Satsuma Pharmaceuticals (NASDAQ:STSA) last released its quarterly earnings results on Tuesday, May 12th. The financial services provider reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). Sell-side analysts expect that Satsuma Pharmaceuticals will post -2.9 EPS for the current fiscal year.
In related news, insider Detlef Albrecht sold 1,000 shares of Satsuma Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $25.26, for a total transaction of $25,260.00. Following the completion of the sale, the insider now owns 21,212 shares in the company, valued at approximately $535,815.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Thomas P. O’neil sold 2,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $50,000. The disclosure for this sale can be found here. Insiders have sold a total of 7,115 shares of company stock worth $189,821 over the last quarter. 45.65% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Eventide Asset Management LLC boosted its holdings in shares of Satsuma Pharmaceuticals by 131.4% in the first quarter. Eventide Asset Management LLC now owns 983,382 shares of the financial services provider’s stock valued at $20,562,000 after purchasing an additional 558,382 shares during the period. Ghost Tree Capital LLC bought a new stake in Satsuma Pharmaceuticals during the 1st quarter valued at $2,475,000. Geode Capital Management LLC purchased a new stake in shares of Satsuma Pharmaceuticals in the 4th quarter worth $1,269,000. Janus Henderson Group PLC grew its position in shares of Satsuma Pharmaceuticals by 369.8% during the 1st quarter. Janus Henderson Group PLC now owns 64,376 shares of the financial services provider’s stock worth $1,383,000 after buying an additional 50,672 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Satsuma Pharmaceuticals by 30.6% during the first quarter. BlackRock Inc. now owns 213,612 shares of the financial services provider’s stock valued at $4,597,000 after buying an additional 50,079 shares during the period. 79.40% of the stock is currently owned by institutional investors and hedge funds.
Satsuma Pharmaceuticals Company Profile
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device.
Featured Story: Limitations to arbitrage trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.